` ALGS (Aligos Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

ALGS
vs
S&P 500

Over the past 12 months, ALGS has underperformed S&P 500, delivering a return of -35% compared to the S&P 500's +13% growth.

Stocks Performance
ALGS vs S&P 500

Loading
ALGS
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ALGS vs S&P 500

Loading
ALGS
S&P 500
Difference
www.alphaspread.com

Performance By Year
ALGS vs S&P 500

Loading
ALGS
S&P 500
Add Stock

Competitors Performance
Aligos Therapeutics Inc vs Peers

S&P 500
ALGS
ABBV
AMGN
GILD
VRTX
Add Stock

Aligos Therapeutics Inc
Glance View

Market Cap
56m USD
Industry
Biotechnology

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The company is headquartered in South San Francisco, California and currently employs 93 full-time employees. The company went IPO on 2020-10-16. The firm is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. The company uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. The company is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). The company developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The firm's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.

ALGS Intrinsic Value
4.11 USD
Overvaluation 55%
Intrinsic Value
Price
Back to Top